Specify a stock or a cryptocurrency in the search bar to get a summary
BeyondSpring Inc
BYSIBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York. Address: 28 Liberty Street, New York, NY, United States, 10005
Analytics
WallStreet Target Price
1.13 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BYSI
Dividend Analytics BYSI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BYSI
Stock Valuation BYSI
Financials BYSI
Results | 2019 | Dynamics |